Board of Directors
Board of Directors 2018
Ian Davis, Chair
Professor Ian Davis is chair of the ANZUP Board and of its Scientific Advisory Committee. He is a medical oncologist and Professor of Medicine and Head of the Eastern Health Clinical School, Monash University and Eastern Health, in Melbourne, Australia. He is an Associate Professor of the University of Melbourne, and Associate of the University of Sydney. His primary clinical interests are in urologic cancers, and his primary research interests are in cancer immunology and the biology of urologic cancers. Prof Davis is a member of the Medical & Scientific Committee and of the Standing Subcommittee on Research for the Cancer Council Victoria. He founded the Urologic Oncology Group of the Clinical Oncology Society of Australia (COSA), is a member of COSA Council, and was previously a COSA Board director.
Joe Esposito, Deputy Chair
Mr Joe Esposito is a Melbourne based director who has recently established a business consultancy practice, Grumentum Capital Pty Ltd. For 8 years until 2020, he owned and operated a BOQ (Bank of Queensland) branch in the inner city suburb of Collingwood. He has had over 20 years experience in corporate banking in Australia and New Zealand. Between 2003 and 2006 he was the CEO of ASX listed Jetset Travelworld Limited.
Mr Esposito has a close affinity with the objectives of ANZUP and the needs of cancer consumers. His qualifications include a Bachelor of Commerce, a Master of Applied Finance and a Diploma in Finance and Mortgage Management. He is a graduate member of the Australian Institute of Company Directors.
Nick Buchan
Dr Nick Buchan is a Urologist based in Christchurch, New Zealand and works in both public and private practice. Nicks practice focuses on the diagnosis and management of urological cancers. Nick gained his experience in medical trials while on fellowship at the Vancouver Prostate Centre. The Vancouver Prostate Centre is one of the largest research and clinical centres in the world that focuses on translational research into prostatic diseases, prostate cancer in particular. Currently Nick is managing director of the Canterbury Urology Research Trust (CURT). CURT is a trust that conducts urological trials for contract research organisations (CROs) as well as its own investigator lead trials in urological conditions with the main focus being urological oncology. Nick is also a previous director of a privately owned hospital in Christchurch, Forte Health and managing director of a large Urology specialist practice, Urology Associates.
Martin Dowling
Mr Martin Dowling has held executive and senior management level financial and commercial roles at some of the largest companies in the world. He has delivered in leadership roles against a broad portfolio of responsibilities across a range of industries including mining, mining services, manufacturing and engineering. He has a Bachelor of Commerce and MBA degree and is a Fellow of CPA Australia and a graduate member of the Australian Institute of Company Directors. He is committed to the pursuit of charitable and societal goals as a Director on not-for-profit boards and also actively in the local community.
Glenn Ferguson
Mr Glenn Ferguson AM is a Solicitor of the High Court of Australia and the Supreme Court of Queensland. He is a past President of the Law Council of Australia and past President of Lawasia the law association for Asia and the Pacific and a past President of the Queensland Law Society. He is also a Senior Counsellor with the Queensland Law Society and has previously chaired their professional standards committee. Glenn is a Founding Fellow of the Australian Academy of Law, a Fellow of the Australian Institute of Company Directors and a Fellow of the Australia and New Zealand College of Notaries. He was appointed the inaugural Adjunct Professor in Law at the University of the Sunshine Coast. He is currently Chair Lexon Insurance and a Governor of the College of Law and Managing Director of FC Lawyers. He has been appointed by both Federal and State Governments to various advisory boards and task forces in the legal, business and immigration sectors. In the 2015 Australia Day Honours, Glenn was made a Member of the Order of Australia “For significant service to the law and to the legal profession, both nationally and in the Asia Pacific region, and to the community”.
Lisa Horvath
Professor Lisa Horvath is the Director of Research at Chris O’Brien Lifehouse. She completed medical school at the University of Sydney and trained in medical oncology at Royal Prince Alfred Hospital, where she was appointed to the senior staff in 2003. She completed her PhD in translational research at the Garvan Institute of Medical Research in 2004. Lisa’s research interest is predominantly in the field of prostate cancer in particular biomarkers, prostate cancer biology and clinical trials.
Lisa holds academic appointments at both the University of Sydney and the University of New South Wales and is the Head of Advanced Prostate Cancer research group at The Kinghorn Cancer Centre/Garvan Institute of Medical Research. She is the Conjoint Chair of Medical Oncology (Genitourinary Cancers) at Lifehouse. She has published more than 140 original research papers in peer-reviewed journals in the last 20 years. She has presented extensively at national and international meetings both peer-reviewed and invited presentations. Lisa is an ANZUP Board Director, a member of the ANZUP Scientific Advisory Committee and is Chair of the ANZUP Prostate Cancer Subcommittee.
Shomik Sengupta
Professor Shomik Sengupta is Professor of Surgery and deputy Head of School at the Eastern Health Clinical School, Monash University and a consultant urologist and Uro-Oncology lead at the Department of Urology, Eastern Health. Shomik has a practice with a uro-oncology subspecialty interest – including open, laparoscopic and robotic cancer surgery. Shomik also has a strong interest in urologic research, including involvement in clinical trials through the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, where he is a member of the Board and the Scientific Advisory Committee. Shomik has more than 130 original publications to date and has been an invited speaker, session chair and convenor at numerous scientific meetings.
Henry Woo
Professor Henry Woo is a urological surgeon who subspecialises in prostate disease. He is the Director of Uro-Oncology and Professor of Robotic Cancer Surgery at the Chris O’Brien Lifehouse. He is also Professor of Urology in the College of Health and Medicine at the Australian National University. Additionally, he is the Head of the Department of Urology, the Director of the SAN Prostate Centre of Excellence and Deputy Chair of the Medical Advisory Committee at the Sydney Adventist Hospital. He has published widely in major urological journals. He is an Associate Editor of the Société Internationale d'Urologie Journal and serves on the journal editorial boards of World Journal of Urology, Prostate Cancer and Prostatic Diseases, Prostate International, Asian Journal of Urology and World Journal of Men’s Health. He is a Fellowship elected Councillor (Board Director) of the Royal Australasian College of Surgeons and has recently been appointed as Chair of the Australian and New Zealand Association of Urological Surgeons and as a Board Director of the Urological Society of Australian and New Zealand. He also serves on the board of the charitable Australian Urological Foundation (AUF) and is a member of the Executive Committee of the Asian Pacific Prostate Society (APPS).
Margaret McJannett, CEO Ex-officio
Ms Margaret McJannett is the Chief Executive Officer (CEO) for ANZUP Cancer Trials Group Ltd. Her professional background is in nursing with a post-graduate certificate in oncology nursing. Margaret worked as a clinical nurse consultant at The Sydney Melanoma Unit, research coordinator in the Medical Psychology Research Unit, Sydney University and project officer at the Queensland Institute of Medical Research in Brisbane. Ms McJannett more recently was the EO of the Clinical Oncological Society of Australia (COSA) and Cancer Council Australia before taking up her role with ANZUP. She has facilitated and contributed to COSA's and CCA's expert committees, the national Cancer Co-operative Clinical Trials Groups and COSA's collaborative role with key stakeholders including other NGO's Cancer Voices, Government agencies and Industry partners.